Please note that all agenda timings are Eastern Time
8:00 am
Registration & Networking Coffee
8:50 am Chairman’s Opening Remarks
Biomarker Targeting Through Multimodal Imaging Applications
9:00 am Building on the Key Relationship: Setting the Goals Between Industry & Academic Imaging
9:20 am Development of Molecularly Targeted Imaging Agents to Advance Cancer Stratification & Treatment
9:40 am Why Imaging Biomarkers Fail?
10:10 am Pitfalls and Promises in the Development of Imaging Biomarkers for Drug Development in Oncology
10:30 am Interactive Panel Discussion – Developing an Imaging Biomarker Strategy
11:00 am
Virtual Speed Networking & Refreshments
Preclinical Technical Advances Across Imaging Modalities
11:30 am Assessing the Effects of VEGF Blockade in Preclinical Tumor Models Using Non-Invasive Imaging Modalities
11:50 am Chemical Tools for Dynamic & Multicolor Optical Imaging In Vivo
12:10 pm Bridging the Preclinical-Clinical Gap
12:30 pm Interactive Panel Discussion
1:00 pm
Networking & Lunch Break
Advancing Imaging Strategy to Create Robust Translational Outcomes
2:00 pm Multimodal Applications to Understand the Tumor Microenvironment
2:20 pm Multimodal Imaging for Improved Drug Efficacy Understanding
2:40 pm An AI-Powered Digital Pathology Toolbox to Advance Oncology Biomarker Development
3:00 pm Panel Discussion – The Future of Digital Pathology: Challenging Traditional Standard of Care Guidelines with AI Data
3:30 pm
Networking Afternoon Break
Exploring Novel Modalities across Preclinical & Clinical Stages
4:00 pm Evaluating Drug Response From Data Analysis to Advance Candidate Development
4:20 pm Multimodal Imaging for Translating Stem Cell-Based Therapy into the Clinic
4:40 pm Imaging the Tumor Environment
5:00 pm Roundtable Discussions
Synopsis
Roundtable A: Cost Effectiveness of Utilizing Targeted Imaging to Improve Clinical Trial Outcomes
Roundtable B: Discussing Image Quality vs Quantity – Challenges of Monitoring Tumors in Real Time
Roundtable C: Incorporating the Value of Imaging Agents into PI/II Clinical Trial Design